Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Assets (2016 - 2025)

Historic Assets for Evogene (EVGN) over the last 10 years, with Q3 2025 value amounting to $26.1 million.

  • Evogene's Assets changed N/A to $26.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.1 million, marking a year-over-year change of. This contributed to the annual value of $39.9 million for FY2024, which is 2198.98% down from last year.
  • As of Q3 2025, Evogene's Assets stood at $26.1 million.
  • Evogene's 5-year Assets high stood at $87.5 million for Q2 2021, and its period low was $26.1 million during Q3 2025.
  • Its 5-year average for Assets is $50.6 million, with a median of $51.1 million in 2023.
  • Its Assets has fluctuated over the past 5 years, first soared by 4325.43% in 2021, then crashed by 3527.08% in 2022.
  • Quarter analysis of 5 years shows Evogene's Assets stood at $76.3 million in 2021, then decreased by 26.44% to $56.1 million in 2022, then decreased by 8.95% to $51.1 million in 2023, then decreased by 21.99% to $39.9 million in 2024, then tumbled by 34.56% to $26.1 million in 2025.
  • Its Assets was $26.1 million in Q3 2025, compared to $33.9 million in Q2 2025 and $34.3 million in Q1 2025.